Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

mölnlycke healthcare ab gamlestadsvägen 3c s-402 52 göteborg Švédsko -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

essity hygiene and health ab mölndals bro 2, mölndal se-405 03 göteborg Švédsko -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

essity hygiene and health ab mölndals bro 2, mölndal se-405 03 göteborg Švédsko -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

essity hygiene and health ab mölndals bro 2, mölndal se-405 03 göteborg Švédsko -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

essity hygiene and health ab mölndals bro 2, mölndal se-405 03 göteborg Švédsko -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

essity hygiene and health ab mölndals bro 2, mölndal se-405 03 göteborg Švédsko -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

essity hygiene and health ab mölndals bro 2, mölndal se-405 03 göteborg Švédsko -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

hameln rds s. r. o., slovensko - jodid draselný - 19 - antidota, detoxicantia

Európska únia - slovenčina - EMA (European Medicines Agency)

sandoz gmbh - rituximab - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - antineoplastické činidlá - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. len obmedzené údaje o účinnosti a bezpečnosti pacientov v minulosti liečených monoklonálne protilátky, vrátane rituximab alebo pacientov, žiaruvzdorné na predchádzajúcu rituximab plus chemoterapia. pozri časť 5. 1 pre ďalšie informácie. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rituximab bolo preukázané, že znižujú rýchlosť progresie poškodenia kĺbov, merané podľa x-ray a zlepšiť fyzickú funkciu, keď uvedené v kombinácii s metotrexátom. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).

Európska únia - slovenčina - EMA (European Medicines Agency)

sandoz gmbh - rituximab - lymphoma, non-hodgkin; arthritis, rheumatoid; leukemia, lymphocytic, chronic, b-cell; wegener granulomatosis; microscopic polyangiitis; pemphigus - antineoplastické činidlá - rixathon is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)rixathon is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. rixathon maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. rixathon monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. rixathon is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. rixathon in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukémia (cll)rixathon v kombinácii s chemoterapiou je indikovaný na liečbu pacientov s predtým neliečených a relapsed/žiaruvzdorné chronic lymphocytic leukémia. len obmedzené údaje o účinnosti a bezpečnosti pacientov v minulosti liečených monoklonálne protilátky, vrátane rituximab alebo pacientov, žiaruvzdorné na predchádzajúcu rituximab plus chemoterapia. pozri časť 5. 1 pre ďalšie informácie. reumatoidná arthritisrixathon v kombinácii s metotrexátom je indikovaný na liečbu dospelých pacientov s ťažkou aktívnou reumatoidnou artritídou, ktorí mali nedostatočnú odpoveď alebo neznášanlivosťou na iné ochorenia úprava anti-reumatické drogy (dmard) vrátane jedného alebo viacerých nádorov nekrotizujúci faktor (tnf) inhibítor terapie. rituximab bolo preukázané, že znižujú rýchlosť progresie poškodenia kĺbov, merané podľa x-ray a zlepšiť fyzickú funkciu, keď uvedené v kombinácii s metotrexátom. granulomatosis with polyangiitis and microscopic polyangiitisrixathon, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). rixathon, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisrixathon is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).